Characterisation of local immune responses induced by a novel nano-particle based carrier-adjuvant in sheep

Veterinary Immunology and Immunopathology

Volumn 155, Issue 1-2, 2013, Pages 21-29

  Gamvrellis, Anita ^a,b   Gloster, Simone ^b,d   Jefferies, Meryem ^b   Mottram, Patricia L ^a   Smooker, Peter ^c   Plebanski, Magdalena ^a   Scheerlinck, Jean Pierre Y ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c RMIT UNIVERSITY   (Australia)

^d CSL LIMITED   (Australia)

Author keywords

Adjuvants; Nano beads; Ovine; Vaccines

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; OVALBUMIN; POLYSTYRENE; T LYMPHOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPH NODE; NONHUMAN; PARTICLE SIZE; VACCINATION;

MUS; OVIS; OVIS ARIES;

ADJUVANTS; NANO-BEADS; OVINE; VACCINES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; IMMUNITY, HUMORAL; LYMPHOCYTE ACTIVATION; MICE; NANOPARTICLES; OVALBUMIN; PARTICLE SIZE; POLYSTYRENES; SHEEP, DOMESTIC; VACCINES, CONJUGATE;

EID: 84881029970     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2013.05.015     Document Type: Article

References (38)

1. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998, 392:86-89.
2. Allsopp C.E., Plebanski M., Gilbert S., Sinden R.E., Harris S., Frankel G., Dougan G., Hioe C., Nixon D., Paoletti E., Layton G., Hill A.V. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur. J. Immunol. 1996, 26:1951-1959.
3. Beacock-Sharp H., Donachie A.M., Robson N.C., Mowat A.M. A role for dendritic cells in the priming of antigen-specific CD4+ and CD8+ T lymphocytes by immune-stimulating complexes in vivo. Int. Immunol. 2003, 15:711-720.
4. Belardelli F., Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 2002, 23:201-208.
5. Crozat K., Guiton R., Contreras V., Feuillet V., Dutertre C.A., Ventre E., vu Manh T.P., Baranek T., Storset A.K., Marvel J., Boudinot P., Hosmalin A., Schwartz-Cornil I., Dalod M. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J. Exp. Med. 2010, 207:1283-1292.
6. De Gregorio E., D'Oro U., Wack A. Immunology of TLR-independent vaccine adjuvants. Curr. Opin. Immunol. 2009, 21:339-345.
7. Demento S.L., Eisenbarth S.C., Foellmer H.G., Platt C., Caplan M.J., Mark Saltzman W., Mellman I., Ledizet M., Fikrig E., Flavell R.A., Fahmy T.M. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009, 27:3013-3021.
8. den Haan J.M., Lehar S.M., Bevan M.J. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 2000, 192:1685-1696.
9. Emery D.L., Rothel J.S., Wood P.R. Influence of antigens and adjuvants on the production of gamma-interferon and antibody by ovine lymphocytes. Immunol. Cell Biol. 1990, 68(Pt. 2):127-136.
10. Falo L.D., Kovacsovics-Bankowski M., Thompson K., Rock K.L. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1995, 1:649-653.
11. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., McKenzie I.F., Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 2004, 173:3148-3154.
12. Fifis T., Mottram P., Bogdanoska V., Hanley J., Plebanski M. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. Vaccine 2004, 23:258-266.
13. Gamvrellis A., Leong D., Hanley J.C., Xiang S.D., Mottram P., Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell Biol. 2004, 82:506-516.
14. Greenwood D.L., Dynon K., Kalkanidis M., Xiang S., Plebanski M., Scheerlinck J.P. Vaccination against foot-and-mouth disease virus using peptides conjugated to nano-beads. Vaccine 2008, 26:2706-2713.
15. Haig D.M., Deane D.L., Myatt N., Thomson J., Entrican G., Rothel J., Reid H.W. The activation status of ovine CD45R+ and CD45R- efferent lymph T cells after orf virus reinfection. J. Comp. Pathol. 1996, 115:163-174.
16. Haig D.M., Hopkins J., Miller H.R. Local immune responses in afferent and efferent lymph. Immunology 1999, 96:155-163.
17. Hardy C.L., LeMasurier J.S., Belz G.T., Scalzo-Inguanti K., Yao J., Xiang S.D., Kanellakis P., Bobik A., Strickland D.H., Rolland J.M., O'Hehir R.E., Plebanski M. Inert 50-nm polystyrene nanoparticles that modify pulmonary dendritic cell function and inhibit allergic airway inflammation. J. Immunol. 2012, 188:1431-1441.
18. Innes E.A., Panton W.R., Sanderson A., Thomson K.M., Wastling J.M., Maley S., Buxton D. Induction of CD4+ and CD8+ T cell responses in efferent lymph responding to Toxoplasma gondii infection: analysis of phenotype and function. Parasite Immunol. 1995, 17:151-160.
19. Kovacsovics-Bankowski M., Clark K., Benacerraf B., Rock K.L. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. USA 1993, 90:4942-4946.
20. Li M., Davey G.M., Sutherland R.M., Kurts C., Lew A.M., Hirst C., Carbone F.R., Heath W.R. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J. Immunol. 2001, 166:6099-6103.
21. Matzinger P. Tolerance, danger and the extended family. Annu. Rev. Immunol. 1994, 12:991-1045.
22. Moron G., Rueda P., Casal I., Leclerc C. CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J. Exp. Med. 2002, 195:1233-1245.
23. Mottram P.L., Leong D., Crimeen-Irwin B., Gloster S., Xiang S.D., Meanger J., Ghildyal R., Vardaxis N., Plebanski M. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol. Pharm. 2007, 4:73-84.
24. Peng S., Frazer I.H., Fernando G.J., Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 1998, 240:147-157.
25. Plebanski M., Gilbert S.C., Schneider J., Hannan C.M., Layton G., Blanchard T., Becker M., Smith G., Butcher G., Sinden R.E., Hill A.V. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur. J. Immunol. 1998, 28:4345-4355.
26. Raychaudhuri S., Rock K.L. Fully mobilizing host defense: building better vaccines. Nat. Biotechnol. 1998, 16:1025-1031.
27. Robson N.C., Beacock-Sharp H., Donachie A.M., Mowat A.M. The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes. Immunology 2003, 110:95-104.
28. Rothel J.S., Jones S.L., Corner L.A., Cox J.C., Wood P.R. The gamma-interferon assay for diagnosis of bovine tuberculosis in cattle: conditions affecting the production of gamma-interferon in whole blood culture. Aust. Vet. J. 1992, 69:1-4.
29. Rudolf M.P., Fausch S.C., Da Silva D.M., Kast W.M. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol. 2001, 166:5917-5924.
30. Scheerlinck J.P., Greenwood D.L. Virus-sized vaccine delivery systems. Drug Discov. Today 2008, 13:882-887.
31. Scheerlinck J.P., Gloster S., Gamvrellis A., Mottram P.L., Plebanski M. Systemic immune responses in sheep, induced by a novel nano-bead adjuvant. Vaccine 2006, 24:1124-1131.
32. Schnorrer P., Behrens G.M., Wilson N.S., Pooley J.L., Smith C.M., El-Sukkari D., Davey G., Kupresanin F., Li M., Maraskovsky E., Belz G.T., Carbone F.R., Shortman K., Heath W.R., Villadangos J.A. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc. Natl. Acad. Sci. USA 2006, 103:10729-10734.
33. Sjolander A., Drane D., Maraskovsky E., Scheerlinck J.P., Suhrbier A., Tennent J., Pearse M. Immune responses to ISCOM formulations in animal and primate models. Vaccine 2001, 19:2661-2665.
34. Tang D., Kang R., Coyne C.B., Zeh H.J., Lotze M.T. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol. Rev. 2012, 249:158-175.
35. van Duin D., Medzhitov R., Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol. 2006, 27:49-55.
36. Windon R.G., Chaplin P.J., Beezum L., Coulter A., Cahil R., Kimpton W., Drane D., Pearse M., Sjölander A., Tennent J.M., Scheerlinck J.-P.Y. Induction of lymphocyte recruitment in the absence of a detectable immune response. Vaccine 2000, 19:572-578.
37. Windon R.G., Chaplin P.J., Beezum L., Coulter A., Cahill R., Kimpton W., Drane D., Pearse M., Sjolander A., Tennent J.M., Scheerlinck J.Y. Induction of lymphocyte recruitment in the absence of a detectable immune response. Vaccine 2000, 19:572-578.
38. Windon R.G., Chaplin P.J., McWaters P., Tavarnesi M., Tzatzaris M., Kimpton W.G., Cahill R.N., Beezum L., Coulter A., Drane D., Sjolander A., Pearse M., Scheerlinck J.P., Tennent J.M. Local immune responses to influenza antigen are synergistically enhanced by the adjuvant ISCOMATRIX. Vaccine 2001, 20:490-497.